Oncology Institute (TOIIW) Return on Capital Employed (2021 - 2026)

Oncology Institute has reported Return on Capital Employed for 6 years, with the latest figure at 37.53% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 1031.0% year-over-year to 37.53%; the trailing twelve-month figure through Mar 2026 stood at 37.53% (up 1031.0% YoY), and the FY2025 full-year result was 36.92%, up 640.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 37.53%, up from 38.73% in the prior quarter.
• The five-year high for Return on Capital Employed was 33.72% in Q4 2022, with the low at 49.24% in Q2 2022.
• Historically, Return on Capital Employed has averaged 43.34% across 5 years, with a median of 44.18% in 2023.
• Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 4452 bps — and 2026, when it jumped 1031 bps.
• Oncology Institute's Return on Capital Employed stood at 33.72% in 2022, then dropped by 28 bps to 43.02% in 2023, then fell by 13 bps to 48.59% in 2024, then increased by 20 bps to 38.73% in 2025, then advanced by 3 bps to 37.53% in 2026.
• The last three Return on Capital Employed figures came in at 37.53% (Q1 2026), 38.73% (Q4 2025), and 42.76% (Q3 2025), per Business Quant data.